Review, Early Access, 2024

Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program

CLINICAL PHARMACOLOGY & THERAPEUTICS, ISSN 0009-9236, 10.1002/cpt.3245

Contributors

Galluppi, Gerald R. [1] [2] Ahamadi, Malidi [3] [4] Bhattacharya, Souvik [5] Budha, Nageshwar [6] Gheyas, Ferdous [7] Li, Chi-Chung [8] [9] Chen, Yuan [8] [9] Dosne, Anne-Gaelle [10] Kristensen, Niels Rode [11] Magee, Mindy [12] Samtani, Mahesh N. [10] Sinha, Vikram [13] Taskar, Kunal [12] Upreti, Vijay V. [14] Yang, Jianning [5] Cook, Jack (Corresponding author) [15]

Affiliations

  1. [1] Sunovion Pharmaceut Inc, US Subsidiary Sumitomo Pharma Amer, Marlborough, MA USA
    2. [NORA names: United States; America, North; OECD];
  2. [2] Sunovion Pharmaceut Inc, US Subsidiary Sumitomo Pharma Amer, Marlborough, MA USA
    3. [NORA names: United States; America, North; OECD];
  3. [3] Sanofi, Paris, France
    4. [NORA names: France; Europe, EU; OECD];
  4. [4] Sanofi, Paris, France
    5. [NORA names: France; Europe, EU; OECD];
  5. [5] Astellas Pharma Inc, Chuo City, Japan
    6. [NORA names: Japan; Asia, East; OECD];

Abstract

Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.

Data Provider: Clarivate

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+